01—Abstract
Summary
Summary of the 8-K filed June 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (NYSE: LH) filed a Form 8-K on June 30, 2026 under Item 7.01 (Regulation FD Disclosure) to announce that it will release its second-quarter 2026 financial results before the market opens on Thursday, July 30, 2026.
The company will host a webcast and conference call beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
The filing itself contains no financial results, guidance, or performance figures. Its substance is the scheduling of the earnings release and call. A copy of the June 30, 2026 press release is furnished as Exhibit 99.1, which is the announcement of the earnings date and webcast details; a replay of the webcast will be available on the investor relations website about two hours after the live event and for one year.
The press release describes Labcorp as a global laboratory services company with nearly 71,000 employees serving clients in approximately 100 countries, supporting more than 85%a of new drugs and therapeutic products approved by the FDA in 2025, and performing more than 750 million tests for patients worldwide. For investors, the key takeaway is the timing of the Q2 2026 results and the opportunity to hear management commentary on the call.
02—Key points
Key Highlights
- Labcorp will release Q2 2026 financial results before market open on Thursday, July 30, 2026.
- A webcast and conference call will begin at 9:00 a.m. ET on July 30, 2026 to discuss the results.
- The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
- A webcast replay will be available on the investor relations website approximately two hours after the live event and for one year.
- The filing is a Regulation FD disclosure (Item 7.01); it contains no financial results or guidance itself.
- Labcorp reports nearly 71,000 employees, serving clients in approximately 100 countries.
- Labcorp states it supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients worldwide.
03—Questions
Frequently Asked Questions
When will Labcorp report its second-quarter 2026 results?
Labcorp will release its Q2 2026 financial results before the market opens on Thursday, July 30, 2026.
How can investors access the earnings discussion?
Labcorp will host a webcast and conference call beginning at 9:00 a.m. ET on July 30, 2026. A link to the webcast will be available on the Labcorp Investor Relations website.
Will there be a replay of the earnings webcast?
Yes. A replay will be available in the 'News & Events' section of the investor relations website approximately two hours after the live event and will remain available for one year.
Where will the earnings press release and financial information be published?
The earnings press release and accompanying financial information will be posted in the 'News & Events' section of the Labcorp Investor Relations website.
Does this 8-K disclose any financial results?
No. The filing is a Regulation FD disclosure announcing the timing of the Q2 2026 earnings release and webcast; the June 30, 2026 press release furnished as Exhibit 99.1 covers the date and webcast details, not results.
04—Continue